Kura Oncology Inc (KURA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kura Oncology Inc (KURA) has a cash flow conversion efficiency ratio of -0.796x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-85.85 Million) by net assets ($107.88 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Kura Oncology Inc (KURA) balance sheet quality index to measure how much of total assets are equity-financed.
Kura Oncology Inc - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Kura Oncology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check KURA total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Kura Oncology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kura Oncology Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mcmillan Shakespeare Ltd
AU:MMS
|
-0.294x |
|
Yunnan Hongxiang Yixintang
SHE:002727
|
0.069x |
|
Dios Fastigheter AB
ST:DIOS
|
0.019x |
|
Sellas Life Sciences Group Inc
NASDAQ:SLS
|
-0.069x |
|
Supply Network Ltd
AU:SNL
|
0.085x |
|
KSB SE & Co. KGaA
XETRA:KSB
|
0.109x |
|
CHERVON HOLDINGS LTD
F:AZ9
|
N/A |
|
Beijing Topnew Info And Tech Co Ltd
SHE:300895
|
0.032x |
Annual Cash Flow Conversion Efficiency for Kura Oncology Inc (2009–2025)
The table below shows the annual cash flow conversion efficiency of Kura Oncology Inc from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see Kura Oncology Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $174.13 Million | $-64.06 Million | -0.368x | -213.29% |
| 2024-12-31 | $413.64 Million | $134.32 Million | 0.325x | +203.35% |
| 2023-12-31 | $397.27 Million | $-124.82 Million | -0.314x | -19.98% |
| 2022-12-31 | $420.28 Million | $-110.06 Million | -0.262x | -26.90% |
| 2021-12-31 | $506.61 Million | $-104.55 Million | -0.206x | -80.55% |
| 2020-12-31 | $610.90 Million | $-69.83 Million | -0.114x | +54.33% |
| 2019-12-31 | $218.78 Million | $-54.76 Million | -0.250x | +17.18% |
| 2018-12-31 | $160.99 Million | $-48.66 Million | -0.302x | +15.13% |
| 2017-12-31 | $79.86 Million | $-28.44 Million | -0.356x | +20.10% |
| 2016-12-31 | $56.88 Million | $-25.35 Million | -0.446x | -104.14% |
| 2015-12-31 | $82.10 Million | $-17.93 Million | -0.218x | -29526.93% |
| 2014-12-31 | $-3.43 Million | $-2.55K | 0.001x | -99.62% |
| 2013-12-31 | $-123.96K | $-24.42K | 0.197x | -17.18% |
| 2012-12-31 | $-95.35K | $-22.68K | 0.238x | -15.92% |
| 2011-12-31 | $-68.03K | $-19.24K | 0.283x | -39.75% |
| 2010-12-31 | $-40.99K | $-19.24K | 0.469x | -59.14% |
| 2009-12-31 | $-18.60K | $-21.37K | 1.149x | -- |
About Kura Oncology Inc
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapi… Read more